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The autoimmune disease multiple sclerosis (MS) is characterized by relapses in the 
majority of patients. A definitive clinical diagnosis of relapse in MS can be complicated 
by the presence of an infection or comorbid disorder. In this mini-review, we describe 
efforts to develop enhanced imaging techniques and biomarker detection as future tools 
for relapse validation. There is emerging evidence of roles for meningeal inflammation, 
sex hormones, comorbid metabolic or mood disorders, and a dysregulated immune 
profile in the manifestation and severity of relapse. Specific subsets of immune cells likely 
drive the pathophysiology of relapse, and identification of a patient’s unique immunolog-
ical signature of relapse may help guide future diagnosis and treatment. Finally, these 
studies highlight the diversity in terms of relapse presentation, immunological signature, 
and response in patients with MS, indicating that going forward the best approach to 
assessment and treatment of relapse will be multifactorial and highly personalized.
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Multiple sclerosis (MS) is a chronic autoimmune disease, which most commonly presents in a relapse 
and remitting form, called relapsing-remitting MS (RRMS). Approximately 85 to 90% of patients 
with MS will experience one or more relapses, also called flares or exacerbations, at some point in the 
course of their disease (1). MS relapses can manifest as a wide array of symptoms, including fatigue, 
sensory disturbances, and ataxia. Relapse severity generally increases, while recovery decreases with 
age and disease progression (2). Since relapses are associated with inflammatory demyelinating 
lesions, research in recent years has been devoted to uncovering the role of the immune system 
and other physiological factors involved in triggering relapse in RRMS. Here, we describe recent 
advances regarding the etiology, characterization, and validation of relapse.
DeTeRMininG THe vALiDiTY AnD SeveRiTY OF A ReLAPSe
Relapses in RRMS are related to increased inflammatory activity associated with central nervous 
system (CNS) demyelination and new or worsening symptoms lasting at least 1–3 days, but can 
persist for months. The location of the demyelinating lesion affects the presentation of symptoms for 
a given relapse. Due to the etiology of a relapse, it is possible for patients to experience a return of 
symptoms when the body enters a pro-inflammatory state unrelated to their autoimmune disorder, 
such as in the context of an infection. In these instances, the patient experiences a “pseudo-relapse.”
A pseudo-relapse can also be associated with non-inflammation-related changes in body tempera-
ture, which can occur during fever, heat exposure, or exercise. In patients with demyelinated lesions, 
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increases in body temperature can impact the ability of an action 
potential to propagate along an axon, resulting in a conduction 
block (3). Under these conditions, then, a patient will typically 
experience a return or worsening of previous symptoms. The 
physical exam is the primary method used to diagnose relapse, 
while magnetic resonance imaging (MRI) is often used to help 
validate the authenticity of a relapse. Gadolinium enhancement 
of T1-weighted MRI can detect white matter lesions indicative 
of breakdown of the blood–brain barrier. The finding of a new 
lesion indicates recent demyelinating activity, and if anatomically 
consistent with the nature of the symptoms, supports the diag-
nosis of a true relapse. It is important to be able to differentiate 
relapse from infection or other medical comorbidities and treat 
the underlying illness first.
The combination of patient symptoms, objective physical 
exam findings, and neuroimaging results should be compared 
to previous exams to help determine whether a patient is truly 
having a MS relapse. This comparative approach would be greatly 
facilitated by the increased use of existing symptom and disability 
assessment scales and the validation of new ones. The Expanded 
Disability Status Scale (4) is the most widely used neurological 
exam scale in clinical trial settings, but focuses primarily on 
mobility, while the Multiple Sclerosis Functional Composite (5) 
scale is considered more sensitive (6), however, both are time 
consuming. In contrast, the assessing relapse in multiple sclerosis 
(ARMS) questionnaire (7) is a less rigorous, but more practical 
method. If formally validated, the ARMS questionnaire could 
allow clinicians to more effectively evaluate a patient’s percep-
tions of relapse symptoms and quickly identify issues associated 
with a true or pseudo-relapse. Although better methods are 
needed to accurately assess the validity and severity of relapse in 
routine clinical practice, new tools have emerged in recent years 
to facilitate future diagnosis and treatment decisions (Figure 1) 
with the goal of improving patient outcomes.
CORTiCAL PATHOLOGY in ReLAPSe
Cortical pathology and cognitive dysfunction are typically asso-
ciated with progressive forms of late stage MS; however, recent 
studies suggest that gray matter damage begins earlier and can 
increase the severity and progression of RRMS (8). Historically, 
cortical demyelinating lesions could not be detected using con-
ventional MRI techniques. These MRI “invisible” lesions could 
only be accurately identified through a pathological assessment 
using cortical tissue obtained through autopsy or biopsy, which 
made it impractical as a useful clinical diagnostic tool. Although 
more common in secondary progressive MS (SPMS), pathological 
evidence of cortical lesions has also been found in tissue obtained 
from patients recently diagnosed with RRMS (9).
Subpial cortical lesions are often associated with nearby 
meningeal inflammation. Tertiary lymphoid follicles, which are 
ectopic CNS lymphoid structures that attract and maintain B cells 
and T cells (10), have been found to reside in the meninges of 
some MS patients (11). Since the subarachnoid space contains 
the interface between cerebrospinal fluid (CSF) and vasculature, 
it can serve as an entry point for antigen-experienced leukocytes 
into the CNS. Indeed, in the rodent experimental autoimmune 
encephalomyelitis (EAE) model, B  cell accumulation in the 
subarachnoid space and meningeal inflammation is associated 
with clinical symptoms of relapse (12). Although it has not yet 
been technically possible to perform a corollary analysis of this 
type in humans, pathological studies have indicated that the 
presence of these tertiary lymphoid follicles is associated with an 
increased severity of disease progression (11). Therefore, patients 
with and without cortical lesions or ectopic follicular structures 
may represent subpopulations with different disease trajectories, 
which could influence treatment options (8), and necessitates the 
development of better detection methods for these features.
Recent developments in MR imaging techniques have allowed 
for the detection of cortical lesions in vivo and provide for the 
chance to correlate imaging and pathological findings. The use of 
these more sensitive methods including magnetization transfer 
imaging, double inversion recovery, and phase-sensitive inver-
sion recovery MR sequences improves detection of gray matter 
lesions, particularly when done in a high field 7-T scanner (13). 
These imaging techniques have provided evidence that clinical 
symptoms can be associated with cortical lesions during relapse 
(14). Advanced imaging techniques have also allowed for the 
detection of leptomeningeal inflammation, which in some cases 
has been pathologically confirmed to be both associated with fol-
licular structures and in close proximity to subpial demyelinating 
lesions (15). Similar to prior pathology-based studies, leptome-
ningeal enhancements were associated with increased disability, 
and although more common in progressive patients, they were 
also found in 19% of examined RRMS patients. Interestingly, this 
study hints that, in RRMS patients, inflammation in the meninges 
may be transiently associated with cortical lesions and responsive 
to treatments during relapse. These new techniques will help 
improve our understanding of how cortical lesions occur in 
RRMS patients and the ability to do longitudinal studies assessing 
the effect of cortical lesions on relapse severity and progression 
from RRMS to SPMS.
BiOMARKeRS FOR MS ReLAPSe
The detection of gadolinium-enhanced T1 lesions is currently 
the “gold standard” in terms of authenticating relapse in RRMS. 
However, MRI is a costly and time-intensive procedure and 
not the most practical diagnostic tool, particularly for patients 
who reside far from major medical centers. Additionally, the 
frequent use of gadolinium-based contrast agents can result in 
the development of gadolinium brain deposits in some patients 
(16). Unfortunately, an alternative imaging technique, diffusion-
weighted imaging suffers from a high false positive rate (17), 
and traditional MS diagnostic markers in CSF, such as IgG, and 
oligoclonal bands, have not been shown to carry prognostic value 
for relapse (18). Since biomarkers have been used to identify 
and predict relapse in rheumatoid arthritis (RA) (19), research 
in recent years has sought to find a similar panel of markers for 
RRMS. At this point, no definitive markers have been identified, 
but some promising candidates have emerged.
RRMS is associated with demyelinating inflammatory activity 
and the immune cells driving this inflammation have particular 
biochemical signatures in terms of the genes they express and 
FiGURe 1 | emerging methods to validate and monitor treatment for multiple sclerosis (MS) relapse. This schematic provides an outline of how currently 
available and emerging tools could be used to help validate the diagnosis of MS relapse, as determined through a physical exam. Assessment scales are currently 
the easiest, but subject to patient biases, and advanced imaging techniques the most reliable, but least accessible. Biomarkers are emerging as a new avenue to 
bridge this divide, but still require further clinical validation. Diagnosis can be confounded by comorbid disorders, the presence of which can also impact treatment 
decisions. If patients are diagnosed with a true relapse, the choice of treatment will depend on severity, and effectiveness can be monitored using the relapse 
validation tools.
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substances they secrete. Expression studies in MS patients have 
revealed major changes in immune system-related genes that are 
associated with the presence or severity of disease, particularly 
in B cells and T cells (20). Consequently, there has been a recent 
focus on the identification of factors, which convey the state of 
the immune system, in addition to those associated with active 
demyelination, in order to uncover a signature for MS relapse.
As a disease of the CNS, the most accurate indicators of RRMS 
disease activity are likely to reside within the CNS. Therefore, CSF 
potentially represents the best source for biomarkers. Levels of 
neurofilament light (NF-L) in CSF from MS patients has been 
found to be increased during active relapse and correlated with 
disease activity (21); however, NF-L is associated with axon loss 
in a variety of neurodegenerative disorders (22), and thus is not 
truly specific to RRMS relapse. The chemokine CXCL13 is indica-
tive of inflammation and has also been found to be elevated in the 
CSF during relapse (23). As a potent B cell attractant involved 
in lymphoid follicle formation, we believe it may also serve as a 
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readout of meningeal inflammation and CNS tertiary lymphoid 
structures, though that has yet to be tested. Similar to NF-L, 
increased CXCL13 levels are not specific to MS, but, in combina-
tion, may be more diagnostically predictive. Moreover, although 
CSF markers may be the most direct readouts of disease activity, 
obtaining CSF samples through lumbar puncture to validate 
relapse may not be clinically practical, which has propelled the 
effort to identify serum biomarkers.
The prognostic utility of peripheral serum biomarkers is 
supported by the diagnostic reproducibility of factors con-
tained in both CSF and blood. Indeed, serum levels of both 
NF-L (24) and CXCL13 (25) are also associated with RRMS 
disease activity. mRNA expression studies in peripheral blood 
mononuclear cells (PBMCs) have shown that expression of the 
T cell cycle regulator RGC-32 decreases, whereas the cytokine 
IL-21 increases during acute relapses, compared to patients 
with stable RRMS (26).
Small non-coding RNAs, particularly microRNAs (miRNAs), 
which can be secreted in extracellular vesicles, are critical for 
the development and regulation of immune cells (27). Thus, 
assaying miRNAs from PBMCs and sera indicate not only the 
overall inflammatory state but also specify whether the immune 
system is acting in a beneficial or pathogenic manner. miR-155, 
which promotes pathogenic helper T cell and pro-inflammatory 
myeloid cell activation, is elevated during relapse and responds to 
disease-modifying therapy (DMT) (28).
Another study found evidence of small non-coding RNAs, 
which change in a bidirectional manner between relapse and 
remitting phases (29), including miR-18b, which has also 
been associated with poor prognosis in B  cell lymphoma (30). 
Interestingly, some of these were sex dependent (29) and may 
be related to the role of estrogen in immune system regulation. 
Since infections can trigger similar immune responses, the use of 
immune system-associated factors alone would not be able to def-
initely discriminate between a true relapse and a pseudo-relapse. 
Once again, reliability would be increased by the incorporation 
of demyelination-related markers.
Stool samples, as a readout of the gut collective microbial com-
munity (microbiota), may also be the valuable source of biomark-
ers for MS relapse [for comprehensive review of the topic, see Ref. 
(31)]. The microbiota is a key integrated component of human 
biological systems, which influences the physiological systems of 
the host, particularly the immune system, both systemically (32) 
and in the CNS (33). The intestinal microbial community can 
regulate blood–brain barrier permeability (34) and demyelina-
tion (35) and thus may be associated with MS relapse risk (36, 
37). Indeed, a recent pilot longitudinal study in pediatric MS 
patients found that the absence of the phylum Fusobacteria in 
the gut was associated with an increased risk of relapse compared 
to patients in which this phylum was present (38). Further studies 
will be required to confirm these findings and determine if they 
are predictive of relapse.
A recent study exploring the use of serum-derived cytokines 
as biomarkers in pediatric MS demonstrating that the ratio 
of IL-10 to other pro- and anti-inflammatory cytokines has 
predicative power for relapse (39) highlights the need for a com-
parative approach involving several markers. Additionally, since 
treatments affect many of these markers (40), it will be critical to 
have a baseline reading for each patient, and then a longitudinal 
assessment following treatment, looking at the profile for both 
relapsing and remitting conditions to determine which mark-
ers have the greatest prognostic value for a particular patient. 
Furthermore, the concentration of some inflammation-related 
serum biomarkers varies in a circadian manner, thus taking into 
account the time of day that samples are collected is vital to make 
meaningful comparisons (41). It is also possible that the valid-
ity of particular markers will change over the course of disease 
progression. Ultimately, the use of biomarkers is going to need to 
be multifactorial and highly personalized.
COMORBiDiTieS
Comorbidities have been shown to affect disease progression, 
time to initiation of DMT, as well as compliance (42), which 
may be related to the increased mortality of these patients as 
compared to the general MS population (43). The presence 
of a comorbidity can affect the onset and severity of relapse. 
Comorbidities can negatively impact sleep in MS patients (44), 
which can, in turn, lead to a worsening of symptoms, especially 
fatigue and pain. Sleep is critical for the proper functioning of 
the immune system. The circadian regulation of cytokine output 
produces a daily rhythm in the inflammatory profile, with a pro-
inflammatory state occurring at night (45). Disrupted sleep can 
interfere with this pattern leading to prolonged periods of inflam-
mation throughout the day, thereby exacerbating symptoms (46). 
Additionally, the circadian rhythmicity of key components of the 
immune system has been shown to be dysregulated in MS patients 
(41). Circadian sleep disorders are common in MS patients (47) 
and could be tied to a disruption in melatonin production, which 
is important in sleep–wake cycle regulation. Melatonin helps 
dampen the overactive immune system (48) and low levels are 
associated with relapse (49) and depression (50). Moreover, sleep 
disturbances and fatigue are strongly associated with depression 
in MS patients (51).
Psychiatric disorders, particularly, depression and anxiety 
are found at a higher frequency among MS patients (52). These 
conditions can affect a patient’s perception of relapse as well as her 
tolerance of symptoms, which can further blur the line between 
a real and a pseudo-relapse. Thus, a better assessment of the 
validity and severity of relapse would benefit these patients. In 
a recent study, depression has been found to be correlated with 
relapse severity (53). Depression can also be related to drug and 
alcohol abuse, which can further exacerbate motor and cogni-
tive impairments during relapse (54). Furthermore, screening 
for depression both prior to and after treatment is critical when 
administering high dose corticosteroids for relapse, as these drugs 
have been associated with increased risk of attempted suicide 
(55). Alleviating depressive symptoms through a combination of 
antidepressants (56) and cognitive behavioral therapy (57) can 
help with symptom relief in some patients. Since antidepressants 
can affect the immune system and adverse side effects can lead to 
non-compliance, depression treatments need to be individually 
tailored based on tolerance, DMT, and social support system (58). 
As cognitive behavioral therapy can also improve sleep quality 
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(59), it may be the preferred option for those affected by both 
mood and sleep disorders.
Physical comorbidities and lifestyle factors can also affect 
relapse. Diet is a modifiable lifestyle factor, which can impact the 
severity of disability and relapses in MS patients (60). A poor diet 
is also associated with the development of metabolic disorders 
such as obesity and diabetes. Obesity, particularly during ado-
lescence, has emerged as a risk factor for developing MS (61), 
and obese MS patients experience higher rates of comorbidities 
and greater disability (62). This is believed to stem from the pro-
inflammatory effects of adipokines released from adipose tissue 
(63). Central obesity, as defined by increased waist circumfer-
ence, is often indicative of metabolic syndrome, and is suggested 
to be a more potent risk factor than body mass index alone (64). 
Consequently, efforts to promote a healthy weight and positively 
impact metabolic function can be beneficial for MS patients. 
Indeed, a recent study showed that treatment of diabetes, irrespec-
tive of MS treatment condition, could improve both metabolic 
condition and MS relapse rate (65). Therefore, the treatment of 
a comorbidity can sometimes positively impact relapse rates and 
improve patient outcomes. In contrast, some MS treatments have 
been implicated in the exacerbation of comorbidities (66), which 
could in turn negatively impact the prognosis of the patient in 
the long run. For example, corticosteroid treatment can cause 
hyperglycemia and exacerbate comorbid diabetes. However, if 
MS symptoms continue to worsen, it may be necessary to switch 
to a more potent DMT (67). Since patients with comorbidities 
are generally excluded from clinical trials, more work needs to 
be done at assessing the best treatment combinations for patients 
with comorbidities.
SeX HORMOneS AnD MS ReLAPSe
Unlike many other physiological states, which can exacerbate 
MS, pregnancy usually results in temporary relief from RRMS 
activity. A meta-analysis concluded that pregnancy is associ-
ated with a significant decrease, while the postpartum period 
is associated with an increase in MS activity (68). Levels of sex 
steroids including estrogen and progesterone fluctuate naturally 
during a woman’s menstrual cycle, and some patients with RRMS 
report increases in relapse rate or severity during the luteal 
phase, when the ratio of estrogen to progesterone is lowest (69). 
Women with RRMS have also been found to have lower levels 
of estrogen during the follicular phase, as compared to healthy 
controls (70). Similarly, when taking hormone-based oral con-
traceptives, women report increased symptoms during the week 
when hormones are absent from the pill (71). Furthermore, the 
onset of menopause is associated with the worsening of MS 
(72). Interestingly, a similar trend of symptomatic relief during 
pregnancy and increased relapse severity during menopause and 
postpartum periods has been noted for RA patients (73), sug-
gesting a common role for estrogen in these two inflammatory 
autoimmune disorders.
A growing number of candidates have emerged as potential 
complementary or alternative treatments for MS (74), which are 
used in conjunction with traditional DMTs. Some guidelines 
have been proposed to inform patients and practitioners about 
the likely safety and efficacy of these adjuncts (75). However, it 
will ultimately be necessary to clinically validate these comple-
mentary treatments with a variety of DMTs, since the mechanism 
of the primary therapy could influence the function or efficacy 
of the adjunct. Recently, the therapeutic value of female sex 
hormones in RRMS on relapse has been investigated in phase 
2 clinical trials. These phase 2 trials have demonstrated a thera-
peutic benefit for estrogen when used in combination with the 
DMTs glatiramer acetate (76) and interferon-β (77) and warrant 
further phase 3 studies. The role of progesterone is less clear, as 
the study investigating its use was terminated prematurely (78). 
In the context of RA, however, hormone replacement therapy 
is generally not advised for postmenopausal women due to the 
small degree of benefit in relation to the risk of cardiovascular 
side effects (79, 80). The use of oral contraceptives has generally 
been found to be neutral (81) or beneficial (82) for RRMS, but 
the outcome may be related to progestin content (83). Since birth 
control pills vary in terms of potency and composition of sex 
steroids, they may also differentially affect relapse rate and MS 
progression.
Estrogen is involved in anti-inflammatory processes and can 
affect the release of cytokines and chemokines from immune 
cells. Estrogen has also been shown to induce beneficial T regula-
tory cells in rodent EAE models and in humans (84). It has also 
been reported that in men with MS, serum levels of sex hormones 
and the level of estrogen receptors localized to the T regulatory 
cells are decreased (85), suggesting that the role of estrogen in 
MS is not restricted to women. While estrogen treatment is not a 
clinically viable treatment for men, testosterone is widely under-
stood to be protective against autoimmune disorders, including 
MS. Indeed, decreased testosterone levels are risk factors for the 
development of MS in men (86). A small study recently reported 
a beneficial effect of testosterone therapy in reducing gray mat-
ter loss and associated cognitive decline (87), which may be 
related to the ability of androgens to act as re-myelination agents 
(88). Furthermore, the anti-inflammatory properties of both 
estrogens and androgens may converge on similar mechanisms 
toward the induction and expansion of T regulatory cells (89). 
Future research devoted to increasing our understanding of the 
underlying physiology for MS may help tailor the development of 
therapeutics, which benefit both genders.
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